-$0.15 EPS Expected for Trevena Inc (TRVN) This Quarter

Analysts forecast that Trevena Inc (NASDAQ:TRVN) will report earnings of ($0.15) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Trevena’s earnings. Trevena reported earnings of ($0.24) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 37.5%. The company is expected to announce its next earnings results on Wednesday, March 6th.

According to Zacks, analysts expect that Trevena will report full year earnings of ($0.55) per share for the current financial year. For the next fiscal year, analysts expect that the business will post earnings of ($0.62) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Trevena.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.00 million.

Several research firms have recently weighed in on TRVN. JMP Securities upped their price target on shares of Trevena from $4.00 to $15.00 and gave the company an “outperform” rating in a report on Friday, October 12th. Zacks Investment Research upgraded shares of Trevena from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Thursday, November 8th. Jefferies Financial Group cut shares of Trevena from a “buy” rating to a “hold” rating and reduced their price target for the company from $10.00 to $1.00 in a report on Wednesday, October 10th. HC Wainwright reduced their price target on shares of Trevena from $7.00 to $3.00 and set a “buy” rating for the company in a report on Friday, October 12th. Finally, Needham & Company LLC cut shares of Trevena from a “buy” rating to a “hold” rating in a report on Friday, October 12th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Trevena has a consensus rating of “Hold” and a consensus price target of $5.42.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of Trevena by 24.0% in the second quarter. FMR LLC now owns 5,288,100 shares of the biopharmaceutical company’s stock valued at $7,615,000 after buying an additional 1,022,830 shares during the period. Vanguard Group Inc boosted its holdings in shares of Trevena by 29.2% in the third quarter. Vanguard Group Inc now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after buying an additional 592,152 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Trevena by 29.2% in the third quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after buying an additional 592,152 shares during the period. BlackRock Inc. boosted its holdings in Trevena by 151.4% during the third quarter. BlackRock Inc. now owns 1,873,311 shares of the biopharmaceutical company’s stock worth $3,971,000 after purchasing an additional 1,128,041 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Trevena by 112.3% during the second quarter. Millennium Management LLC now owns 1,005,820 shares of the biopharmaceutical company’s stock worth $1,448,000 after purchasing an additional 532,129 shares during the last quarter. Institutional investors own 39.10% of the company’s stock.

NASDAQ:TRVN traded down $0.03 during trading hours on Friday, hitting $0.58. The stock had a trading volume of 1,488,376 shares, compared to its average volume of 667,225. Trevena has a one year low of $0.55 and a one year high of $3.58. The company has a quick ratio of 4.30, a current ratio of 4.30 and a debt-to-equity ratio of 0.16.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

See Also: What are retained earnings?

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply